FindTrial
Sign In

Outcome in patients with small cell lung cancer Multicenter – Outcome in patients with small cell lung cancer – Real-world validation of the outcome in patients with small cell lung cancer after curative-intent radiotherapy as part of multimodal concepts analogous to the ADRIATIC trial

Outcome in patients with small cell lung cancer Multicenter – Outcome in patients with small cell lung cancer – Real-world validation of the outcome in patients with small cell lung cancer after curative-intent radiotherapy as part of multimodal concepts analogous to the ADRIATIC trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00038597
Enrollment
500
Registered
2025-12-09
Start date
2024-05-28
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small-cell lung cancer stage II-III

Interventions

Group 1: Before durvalumab was approved for adjuvant therapy: Radiochemotherapy alone (progression free survival , 18 months ans 24 months, overall survival 24 months, Follow-up time: 24- 60 months)

Sponsors

Universitätsklinikum Essen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: small cell lung cancer

Exclusion criteria

Exclusion criteria: Non-small cell lung cancer

Design outcomes

Primary

MeasureTime frame
progression free survival , 18 months ans 24 months—

Secondary

MeasureTime frame
severe adverse events, overall survival 24 months, Follow-up time: 24- 60 months—

Countries

Germany

Contacts

Public ContactMaja Guberina

Universitätsklinikum

maja.guberina@uk-essen.de0201 723 2322

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026